Effect of baseline age on efficacy and safety of Siponimod in patients with active secondary progressive multiple sclerosis
Siponimod ( Mayzent ) is a selective sphingosine 1-phosphate receptor ( S1P1 and S1P5 ) modulator, approved in the USA for treatment of relapsing forms of multiple sclerosis ( MS ), including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis ( SPMS ).
In the phase 3 EXPAND registration trial in SPMS, Siponimod has significantly reduced risk of 3 month ( primary endpoint ) and 6 month confirmed disability progression ( CDP ) by 21% and 26%, respectively.
The objective of a study was to assess efficacy and safety of Siponimod in patients with active SPMS in subgroups of patients aged less than 45 and greater than or equal to 45 years ( median value ) at baseline.
Post hoc analyses were performed in subgroups of patients with active SPMS, defined as a relapse in the 2 years before screening and/or greater than or equal to 1 T1 gadolinium-enhancing lesion at baseline, randomized to Siponimod 2 mg daily or placebo.
Efficacy endpoints included: time to 3 and 6 month CDP ( as per Expanded Disability Status Scale scores ).
Adverse events, serious adverse events, and adverse events leading to treatment discontinuation were also assessed.
There were 779 patients with active SPMS: 306 patients aged less than 45 years ( Siponimod, n=213; placebo, n=93 ) and 473 patients aged greater than or equal to 45 years ( Siponimod, n=303; placebo, n=170 ).
In those less than 45 years, Siponimod has reduced risk of 3 month CDP by 31.9% compared with placebo ( Siponimod, n=57 [ 26.8% ]; placebo, n=35 [ 37.6% ]; hazard ratio [ HR ], [ 95% confidence interval ( CI ) ]: 0.68, [ 0.45, 1.04 ]; p=0.0734 ), and reduced 6 month CDP risk by 39.5% ( Siponimod, n=44 [ 20.7% ]; placebo, n=30 [ 32.3% ]; HR, [ 95% CI ]: 0.61, [ 0.38, 0.96 ]; p=0.0339 ).
In the subgroup of patients greater than or equal to 45 years, Siponimod has reduced the risk of 3 month and 6 month CDP by 31.5% and 33.1%, respectively, versus placebo ( 3 month: Siponimod, n=72 [ 23.8% ]; placebo, n=56 [ 32.9% ]; HR, [ 95% CI ]: 0.69, [ 0.48, 0.97 ]; p=0.0340; 6 month: Siponimod, n=55 [ 18.2% ]; placebo, n=44 [ 25.9% ]; HR, [ 95% CI ]: 0.67, [ 0.45, 1.0 ]; p=0.0471 ).
Siponimod was generally well tolerated in both subgroups. Rates of any adverse effects were similar for Siponimod and placebo in patients less than 45 years ( 82.6% vs 82.8% ), and slightly higher for Siponimod in those greater than or equal to 45 years ( 89.8% vs 75.9% ).
Rates of adverse effects and adverse effects leading to discontinuation were similar between groups.
In conclusion, in EXPAND, Siponimod has provided similar clinical effects in reducing CDP risk in patients aged less than 45 years and greater than or equal to 45 years with active secondary progressive multiple sclerosis. ( Xagena )
Source: ACTRIMS ( Americas Committee for Treatment and Research in Multiple Sclerosis ) Forum 2020
FDA has approved Ponvory, an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio in reducing annual relapses and brain lesions
The U.S. Food and Drug Administration ( FDA ) has approved Ponvory ( Ponesimod ), a once-daily oral selective sphingosine-1-phosphate...
A small number of patients receiving Dimethyl fumarate ( Tecfidera ) for the treatment of multiple sclerosis have developed progressive...
Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the...
Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis,...
Mayzent for adult patients with secondary progressive multiple sclerosis with active disease, approved in European Union
The European Commission ( EC ) has approved Mayzent ( Siponimod ) for the treatment of adult patients with secondary...
Relapsing multiple sclerosis: Ofatumumab has demonstrated superiority versus Teriflunomide in ASCLEPIOS I and II
Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...